<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="editorial" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Endocrinol.</journal-id>
<journal-title>Frontiers in Endocrinology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Endocrinol.</abbrev-journal-title>
<issn pub-type="epub">1664-2392</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fendo.2024.1362519</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Endocrinology</subject>
<subj-group>
<subject>Editorial</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Editorial: Endocrine disruptors and diseases of brain and mind: past and prelude</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Johri</surname>
<given-names>Ashu</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1338098"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Roncati</surname>
<given-names>Luca</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/64984"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lizcano</surname>
<given-names>Fernando</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/147530"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Independent Researcher</institution>, <addr-line>New York, NY</addr-line>, <country>United States</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Surgery, Medicine, Dentistry and Morphological Sciences with interest in Transplantation, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia</institution>, <addr-line>Modena</addr-line>, <country>Italy</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Centro de Investigacion Biomedica (CIBUS), Doctoral program in Biosciences, Universidad de La Sabana, Ch&#xed;a</institution>, <addr-line>Cundinamarca</addr-line>, <country>Colombia</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited and Reviewed by: Hubert Vaudry, Universit&#xe9; de Rouen, France</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Ashu Johri, <email xlink:href="mailto:johri.ashu@gmail.com">johri.ashu@gmail.com</email>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>17</day>
<month>01</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1362519</elocation-id>
<history>
<date date-type="received">
<day>28</day>
<month>12</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>05</day>
<month>01</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Johri, Roncati and Lizcano</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Johri, Roncati and Lizcano</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<related-article id="RA1" related-article-type="commentary-article" xlink:href="https://www.frontiersin.org/research-topics/48224" ext-link-type="uri">Editorial on the Research Topic <article-title>Endocrine disruptors and diseases of brain and mind: past and prelude</article-title>
</related-article>
<kwd-group>
<kwd>endocrine disrupting chemicals (EDCs)</kwd>
<kwd>organophosphate flame retardants (OPFRs)</kwd>
<kwd>phthalates</kwd>
<kwd>neurodevelopment</kwd>
<kwd>autism</kwd>
<kwd>dementia</kwd>
<kwd>chorea</kwd>
<kwd>Fahr&#x2019;s syndrome</kwd>
</kwd-group>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="5"/>
<page-count count="3"/>
<word-count count="1336"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Neuroendocrine Science</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Perspective</title>
<p>Endocrine disruptors or endocrine disrupting chemicals (EDCs) are structurally diverse synthetic and naturally occurring compounds that interfere with the endocrine system with potentially adverse health outcomes. Relatively low concentrations of EDCs persist in the environment and produce long-term alterations percolating from generation to generations. Exposure to EDCs is associated with cancer, stillbirth or birth defects, developmental disorders, metabolic changes, and is increasingly suspected in the sporadic occurrences of neurological and neuropsychiatric disorders (<xref ref-type="bibr" rid="B1">1</xref>&#x2013;<xref ref-type="bibr" rid="B5">5</xref>). Following is a brief summary of the articles that were published in this Research Topic.</p>
</sec>
<sec id="s2">
<title>Organophosphate flame retardants in young population</title>
<p>Organophosphate flame retardants (OPFRs) are thermally stable organic compounds widely used in many housing materials and consumer products and were thought to be safer alternatives to other previously used versions of flame retardants. However, recent studies have linked these compounds to endocrine disruption, cardiovascular and neurodevelopmental abnormalities, and cancer. As part of a cohort study examining the adverse health effects of OPFRs in a broad range of young population (0-18 years old) in the Southern region of Taiwan, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fendo.2023.1173449">Chen et&#xa0;al.</ext-link> documented the urinary levels of both the parent compounds as well as primary metabolites of OPFRs. They reported that the presence of OPFRs and its metabolites was comparatively higher in newborns and toddlers, which they attributed to the longer time spent indoors for this age group, increasing the likelihood of exposure to house dust, foam, wooden and textile materials. Moreover, in the newborn group they found a negative correlation between some of the OPFR metabolites and birth outcomes such as birth length, birth weight, head circumference, chest circumference and abdominal circumference. However, they did not find a significant correlation between the urinary OPFRs and creatinine levels in the newborns. Although further studies are needed to determine the relationship between OPFRs and the susceptibility to negative health outcomes, this study further supports the usefulness of urinary levels of OPFRs and OPFR metabolites as biomarkers of exposure to OPFRs.</p>
</sec>
<sec id="s3">
<title>Phthalates and neurodevelopment</title>
<p>Phthalates (phthalic acid diesters) are classified as EDCs, are ubiquitous pollutants, and have the ability to cross the placenta. This raises valid concerns for developmental effects from <italic>in utero</italic> exposure, considering the higher susceptibility of the fetus and child. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fendo.2023.1172743">Lucaccioni et&#xa0;al.</ext-link> performed careful and meticulous investigations regarding peri- and postnatal exposure to phthalates in an Italian pediatric cohort of full-term babies and their mothers. They examined the relationship between the urinary levels of phthalate metabolites and global development indices using the Griffiths Scales of Children Development (GSCD) at six months of age. Their studies showed that phthalate exposure is widespread in the area in which the study was undertaken. In line with previous findings, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fendo.2023.1172743">Lucaccioni et&#xa0;al.</ext-link> found negative associations of GSCD III scores such as language and hand-eye coordination in children with higher levels of certain phthalate metabolites. Intriguingly, they found a clear sex-related difference in the impact of phthalates on neurodevelopment. These findings assume significance in light of the previously published studies showing phthalate exposure is associated with a variety of neurodevelopmental outcomes, including autism, attention deficit hyperactivity disorder, reduced IQ, and reduced mental and psychomotor development, while some studies did not find any significant associations. Additional large-scale studies are needed to confirm these findings since humans are chronically exposed to phthalates during all stages of life.</p>
</sec>
<sec id="s4">
<title>EDCs and autism</title>
<p>
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fendo.2023.1184546">Cunha et&#xa0;al.</ext-link> examined the association between maternal exposure to EDCs during pregnancy and the risk of autism spectrum disorders (ASD) in children. Upon thorough research using defined criteria and screening for eligibility, data extraction, and assessment of bias, 27 observational studies were included assessing prenatal exposure to phthalates, polychlorinated biphenyls, organophosphate pesticides, phenols, perfluoroalkyl substances, organochlorine pesticides, brominated flame retardants, dioxins, and parabens. The number of examined children ranged from 77 to 1,556, the age at the assessment of autistic traits ranged from 3 to 14 years, and most studies assessed autistic traits using the Social Responsiveness Scale. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fendo.2023.1184546">Cunha et&#xa0;al.</ext-link> did not find an association between maternal exposure to specific EDCs and a likelihood of autistic traits in the progeny later in life. The authors, however, caution against interpreting this study as definitive evidence of no association between prenatal exposure to EDCs and autistic traits, citing the limitations of studies under examination such as representative exposure assessment, small sample sizes, inadequacy to assess sexually dimorphic effects, or the effects of EDC mixtures. Finally, this review could be helpful to guide future investigators in circumventing the limitations of the examined studies as outlined in this systematic review.</p>
</sec>
<sec id="s5">
<title>Hormones and dementia</title>
<p>Life-long exposure to EDCs, especially estrogenic EDCs, contributes to the superfecta of metabolic syndrome that includes insulin resistance, type 2 diabetes mellitus, diabetes-related dementia and dyslipidemia, and Alzheimer&#x2019;s disease (AD), which is sometimes dubbed as type 3 diabetes. Environmental estrogens and anti-androgens can interfere with normal pancreatic function, insulin signaling pathways, brain insulin resistance and dyslipidemia, leading to diabetes and related dementia. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fendo.2023.1127481">Takechi et&#xa0;al.</ext-link> highlight another dimension to this complex problem as they propose that dyslipidemia and increased plasma abundance of triglyceride rich lipoproteins (TRLs) in type 2 diabetes coalesce and bind amyloid-&#x3b2; peptide (TRL-A&#x3b2;) which in turn compromises cerebral capillary integrity. Further, heightened extravasation of TRL-A&#x3b2; precipitates neurovascular inflammation, resulting in neuronal demise and premature cognitive decline. These studies not only provide new insights for onset and progression of AD but could also potentially open-up new therapeutic avenues.</p>
</sec>
<sec id="s6">
<title>Fahr&#x2019;s syndrome</title>
<p>Fahr&#x2019;s syndrome also known as primary familial brain calcification (PFBC), and familial idiopathic basal ganglia calcification (FIBGC) is a rare, dominantly inherited neurological disorder with abnormal deposits of calcium in the basal ganglia and the cerebral cortex of the brain. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fnins.2023.1226214">Nawaz et&#xa0;al.</ext-link> present the case report of a man who they diagnosed to be suffering from Fahr&#x2019;s syndrome based on neuropsychological and neuroimaging findings. Based on their findings, they propose that autoimmune polyendocrine syndrome should be considered as the etiology of Fahr&#x2019;s syndrome. This is also a first report of an unusual association of neuromyelitis optica spectrum disorder with Fahr&#x2019;s syndrome.</p>
</sec>
<sec id="s7">
<title>Chorea in endocrine diseases</title>
<p>Next in this topic, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fendo.2023.1155638">Zheng and Wu</ext-link> present a unique and comprehensive perspective on chorea as an unusual clinical manifestation of endocrine diseases such as thyroid, parathyroid, diabetes as well as electrolyte disturbances. Chorea is a rare disorder with abrupt, involuntary, dance-like movements and is usually associated with neurological disorders which is why endocrine disease-related chorea is often misdiagnosed. This review provides a detailed account of current knowledge on endocrine disease-related chorea, possible mechanisms involved and recommendations to aid in early diagnosis and treatment of this ailment.</p>
</sec>
<sec id="s8">
<title>Future directions</title>
<p>In conclusion, our Research Topic presents a cautionary tale of past exposures to EDCs and long-term adverse effects of some of these compounds. Sometimes, it is worth revisiting the past to learn the lessons for future generations and in providing a safe and healthy environment for everyone. While technological advances have certainly made our lives easier, it has also taken a toll on overall general well-being of people. Relatively low concentrations of the EDCs are sufficient to produce long-term health problems, sometimes across generations. Thus precautions must be taken to avoid exposure to the toxic chemicals, whether it is through restricted use and safe disposal or by replacing them with safer natural alternatives. With the rising world population, there is obviously a crunch for natural resources and research must continue in this direction to attain sustainability. An important avenue could be the use of artificial intelligence (AI) in deciphering the potential interactions of chemicals with hormonal pathways and the use of adverse outcomes pathways (AOP) for the description of the effect of substances on biological pathways. This could save precious time and resources and help identify and root-out the potentially hazardous compounds from becoming a part of our everyday life.</p>
</sec>
<sec id="s9" sec-type="author-contributions">
<title>Author contributions</title>
<p>AJ: Conceptualization, Investigation, Project administration, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. LR: Writing &#x2013; review &amp; editing. FL: Writing &#x2013; review &amp; editing.</p>
</sec>
</body>
<back>
<sec id="s10" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
<p>The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</p>
</sec>
<sec id="s11" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Modica</surname> <given-names>R</given-names>
</name>
<name>
<surname>Benevento</surname> <given-names>E</given-names>
</name>
<name>
<surname>Colao</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Endocrine-disrupting chemicals (EDCs) and cancer: new perspectives on an old relationship</article-title>. <source>J Endocrinol Invest</source> (<year>2023</year>) <volume>46</volume>:<page-range>667&#x2013;77</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s40618-022-01983-4</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Street</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Bernasconi</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Endocrine-disrupting chemicals in human fetal growth</article-title>. <source>Int J Mol Sci</source> (<year>2020</year>) <volume>21</volume>:<elocation-id>1430</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms21041430</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roncati</surname> <given-names>L</given-names>
</name>
<name>
<surname>Pusiol</surname> <given-names>T</given-names>
</name>
<name>
<surname>Piscioli</surname> <given-names>F</given-names>
</name>
<name>
<surname>Barbolini</surname> <given-names>G</given-names>
</name>
<name>
<surname>Maiorana</surname> <given-names>A</given-names>
</name>
<name>
<surname>Lavezzi</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>The first 5-year-long survey on intrauterine unexplained sudden deaths from the Northeast Italy</article-title>. <source>Fetal Pediatr Pathol</source> (<year>2016</year>) <volume>35</volume>:<page-range>315&#x2013;26</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/15513815.2016.1185751</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lizcano</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>Roles of estrogens, estrogen-like compounds, and endocrine disruptors in adipocytes</article-title>. <source>Front Endocrinol (Lausanne)</source> (<year>2022</year>) <volume>13</volume>:<elocation-id>921504</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fendo.2022.921504</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gollamudi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Johri</surname> <given-names>A</given-names>
</name>
<name>
<surname>Calingasan</surname> <given-names>NY</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Elemento</surname> <given-names>O</given-names>
</name>
<name>
<surname>Beal</surname> <given-names>MF</given-names>
</name>
</person-group>. <article-title>Concordant signaling pathways produced by pesticide exposure in mice correspond to pathways identified in human Parkinson&#x2019;s disease</article-title>. <source>PloS One</source> (<year>2012</year>) <volume>7</volume>:<elocation-id>e36191</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0036191</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>